Pfizer (PFE) Stock Forecast & Price Target

$24.24 +0.32 (+1.32%)

Closing price 08/7/2025 03:59 PM Eastern

Extended Trading

$24.26 +0.02 (+0.08%)

As of 08/7/2025 07:59 PM Eastern

Pfizer - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
1

Hold
11

Buy
6

Based on 18 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 1 has given a sell rating, 11 have given a hold rating, 4 have given a buy rating, and 2 have given a strong buy rating for PFE.

Consensus Price Target

$28.12
15.97% Upside

According to the 18 analysts' twelve-month price targets for Pfizer, the average price target is $28.12. The highest price target for PFE is $33.00, while the lowest price target for PFE is $23.00. The average price target represents a forecasted upside of 15.97% from the current price of $24.25.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

PFE Analyst Ratings Over Time

Type	Current Forecast 8/8/24 to 8/8/25	1 Month Ago 7/9/24 to 7/9/25	3 Months Ago 5/10/24 to 5/10/25	1 Year Ago 8/9/23 to 8/8/24
Strong Buy	2 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)
Hold	11 Hold rating(s)	13 Hold rating(s)	12 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$28.12	$28.55	$28.74	$34.54
Forecasted Upside	15.97% Upside	11.70% Upside	28.98% Upside	20.11% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.39	2.81	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	15.97% Upside	12,688.35% Upside	14.06% Upside
News Sentiment Rating	Positive News See Recent PFE News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/6/2025	Citigroup 3 of 5 stars	Andrew Baum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$25.00 ➝ $26.00	+8.57%
8/6/2025	Morgan Stanley 3 of 5 stars	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00	+37.75%
8/6/2025	Bank of America 4 of 5 stars	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$27.00 ➝ $28.00	+13.41%
5/29/2025	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold	$28.00 ➝ $25.00	+6.66%
5/21/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$32.00 ➝ $33.00	+43.11%
5/19/2025	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$27.00 ➝ $26.00	+12.99%
4/30/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform	$22.00 ➝ $23.00	-5.78%
4/30/2025	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$29.00 ➝ $27.00	+10.61%
4/30/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$28.00 ➝ $26.00	+6.51%
4/30/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral	$25.00 ➝ $27.00	+10.61%
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
4/30/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$24.00 ➝ $25.00	+3.55%
4/22/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold	$32.00 ➝ $28.00	+24.22%
4/22/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00	+8.74%
4/17/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$36.00 ➝ $30.00	+35.57%
3/18/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$36.00 ➝ $32.00	+21.72%
10/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$32.00	+7.89%
8/7/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
8/7/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:06 AM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 5, 2025. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

The current stock price is around $24.49, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
Pfizer Inc. reported strong earnings recently, with earnings per share (EPS) of $0.78, exceeding analyst expectations, indicating robust financial performance.
The company has shown a year-over-year revenue increase of 10.3%, suggesting growth potential and a solid market position.
Pfizer Inc. offers a quarterly dividend of $0.43 per share, translating to an annual yield of 7.0%, which can provide a steady income stream for investors.
Analysts have a consensus target price of $28.28, indicating potential upside from the current stock price, which may attract investors looking for capital appreciation.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

Recent downgrades from various analysts have lowered price targets, with some suggesting a more cautious outlook on the stock's performance.
The stock has a relatively high dividend payout ratio of 124.64%, which may raise concerns about sustainability if earnings do not continue to grow.
Market volatility and economic uncertainties could impact Pfizer Inc.'s stock performance, making it a riskier investment in the current climate.
Despite positive earnings, the stock has not reached its previous highs, indicating potential challenges in maintaining growth momentum.
With a beta of 0.52, the stock is less volatile than the market, which may limit potential gains for investors seeking high-risk, high-reward opportunities.

PFE Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $28.12, with a high forecast of $33.00 and a low forecast of $23.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There is currently 1 sell rating, 11 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
: According to analysts, Pfizer's stock has a predicted upside of 15.97% based on their 12-month stock forecasts.
: Pfizer has been rated by research analysts at Bank of America, Berenberg Bank, Citigroup, HSBC, Jefferies Financial Group, and Morgan Stanley in the past 90 days.
: Analysts like Pfizer less than other "medical" companies. The consensus rating for Pfizer is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PFE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:PFE) was last updated on 8/8/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Stock Forecast & Price Target